Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Cancers|November 27, 2025
Documentation of Advance Care Planning in Early Phase Cancer Clinical Trials: An Australian Single-Centre ExperienceNancy Huang, Joseph Descallar, Samuel Vo, et al.
Journal of Evaluation in Clinical Practice|April 26, 2022
Adapting an integrated care pathway for implementing electronic patient reported outcomes assessment in routine oncology care: Lessons learned from a case studyAdeola Bamgboje-Ayodele, Sandra Avery, Joanne Pearson, et al.
Cancer Immunology, Immunotherapy : CII|October 23, 2019
Pembrolizumab for anaplastic thyroid cancer: a case studyMarra Jai Aghajani, Adam Cooper, Helen McGuire, et al.
Journal of Patient-Reported Outcomes|June 20, 2022
Stepping into the real world: a mixed-methods evaluation of the implementation of electronic patient reported outcomes in routine lung cancer careAfaf Girgis, Adeola Bamgboje-Ayodele, Orlando Rincones, et al.
Pathology|November 19, 2025
Histopathological associations, molecular findings and clinical outcomes of patients with non-small cell lung carcinoma with MET alterations: a 3-year retrospective Australian case seriesJing Jing Li, Jawad Saab, Victoria Bray, et al.
Internal Medicine Journal|September 15, 2023
Utility of multigene panel next-generation sequencing in routine clinical practice for identifying genomic alterations in newly diagnosed metastatic nonsmall cell lung cancerUdit Nindra, Abhijit Pal, Victoria Bray, et al.
Plos One|May 17, 2023
Phase II, double blind, placebo controlled, multi-site study to evaluate the safety, feasibility and desirability of conducting a phase III study of anamorelin for anorexia in people with small cell lung cancer: A study protocol (LUANA trial)Mariana S Sousa, Peter Martin, Miriam J Johnson, et al.
Pathology|June 25, 2024
The histopathological spectrum and molecular changes associated with KRAS G12C mutation in non-small cell lung carcinomaJing Jing Li, Xiao Juan Wu, Mahtab Farzin, et al.
Nature Communications|February 28, 2024
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATELavinia Tan, Chris Brown, Antony Mersiades, et al.
JTO Clinical and Research Reports|September 23, 2024
ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor ResistanceMalinda Itchins, Shirley Liang, Chris Brown, et al.
Pageof 4